Volume : 09, Issue : 05, May – 2022

Title:

21.ALZHEIMER’S DISEASE NOVEL DRUGS: A REVIEW

Authors :

Rudra Pratap Chauhan, Rohit Ahirwar, Sadab Khan, Rubeena Khan, Mrs. Sunayana Kesharwani*

Abstract :

Alzheimer’s disease (AD) is a neurological illness that causes the majority of dementia cases. In today’s increasingly ageing population, the prevalence of Alzheimer’s disease has increased, putting a great strain on families and society. Despite the devastating symptoms of Alzheimer’s disease, present treatments are unable to generate sufficient therapeutic benefits or halt the illness’s progression. Finding new treatments for Alzheimer’s disease has become critical. In this research, we looked at five different types of innovative therapeutic approaches: anti-amyloid therapy, anti-tau therapy, anti-neuroinflammatory therapy, neuroprotective drugs such as N-methyl-D-aspartate (NMDA) receptor modulators, and brain stimulation. The focus of therapeutic development is changing away from a single disease target and toward more complicated mechanisms like neuroinflammation and neurodegeneration. The review focus on Novel Drug used for treatment of alzheimer’s disease.

Cite This Article:

Please cite this article in press Sunayana Kesharwani et al,Alzheimer’s Disease Novel Drugs: A Review.,Indo Am. J. P. Sci, 2022; 09(5).,

Number of Downloads : 10

References:

1. Brookmeyer R, Johnson E, Ziegler G, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007;3:186–91.
2. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews 2006;1:CD005593.
3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006;2: CD003154.
4. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-97.
5. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron1994;13:45-53.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.
7. Iqbal K, Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis. 2006;9:219-42.
8. Iqbal K, Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. Curr Alzheimer Res 2005; 2:335-41.
9. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992; 42: 631–9.
10. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004;1:213-25.
11. Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–584.
12. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after ABeta42 immunization. Neurology 2003;61:46 –54.
13. Woodhouse A, Dickson TC, Vickers JC. Vaccination strategies for Alzheimer’s disease: A new hope? Drugs Aging 2007;24:107-19.
14. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against Beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004 ;75:1472–1474.
15. Rajendran L, Schneider A, Schlechtingen G, et al. Efficient inhibition of the Alzheimer’s disease beta-secretase by membrane targeting. Science 2008;320:520-3.
16. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82.
17. Sun MK, Alkon DL. Protein kinase C isozymes: memory therapeutic potential. Curr Drug Targets CNS Neurol Disord 2005;4:541-52.
18. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93.
19. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003;23:1992–1996.
20. Jacobsen JS, Comery TA, Martone RL, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008;105:8754-9.
21. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer’s disease. J Am Geriatr Soc 2003;51:1143-8
22. Lee JY, Friedman JE, Angel I, et al. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004;25:1315-21
23. Maczurek A, Shanmugam K, Münch G. Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in Alzheimer’s disease. Ann N Y Acad Sci 2008;1126:147-51
24. Lian Q, Ladner CJ, Magnuson D, et al. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer’s disease cerebral cortex. Exp Neurol 2001;167:158-65.
25. Caccamo A, Oddo S, Tran LX, et al. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007;170:1669-75
26. Praticò D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-7.
27. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer’s disease. Ann Pharmacother 2005;39:2073-80.
28. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
29. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901.
30. Farlow MR. NMDA receptor antagonists. A new therapeutic approach for Alzheimer’s disease. Geriatrics 2004;59:22-7.
31. Chappell AS, Gonzales C, Williams J, et al. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007;68:1008-12
32. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 2002;99:12432-7.
33. Pagocic V, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis 2007;4: 443-486
34. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer’s disease. Ann Neurol 2008;63:621-31.
35. Kamal MA, Klein P, Yu QS, et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006;10:43-51
36. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer’s disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-81
37. Dunbar GC, Inglis F, Kuchibhatla R, et al. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007;21:171-8.
38. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
39. Chan A, Shea TB. Folate deprivation increases presenilin expression, gammasecretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine. J Neurochem 2007;102:753-60.